Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors

European Journal of Haematology

Volumn 85, Issue 2, 2010, Pages 139-148

  Giehl, Michelle ^a   Leitner, Armin ^a   Haferlach, Claudia ^b   Duesberg, Peter ^a   Hofmann, Wolf Karsten ^a   Hofheinz, Ralf ^a   Seifarth, Wolfgang ^a   Hochhaus, Andreas ^c   Fabarius, Alice ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Centrosome; chronic myeloid leukemia; cytogenetics; mitotic spindle; solid tumors; tyrosine kinase inhibitors

Indexed keywords

BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TUBULIN;

ADULT; AGED; ARTICLE; CENTROSOME; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFECT; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MALE; MITOSIS SPINDLE; MOUTH MUCOSA; MYELOID LEUKEMIA; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; TREATMENT RESPONSE;

ADULT; AGED; ANILINE COMPOUNDS; CASE-CONTROL STUDIES; CENTROSOME; FEMALE; FIBROBLASTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MOUTH MUCOSA; NITRILES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINOLINES; THIAZOLES;

EID: 77954720429     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01459.x     Document Type: Article

References (53)

1. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 2003 63 : 1398 1404.
2. Giehl M, Fabarius A, Frank O, et al. Centrosome aberrations in chronic myeloid leukemia correlate with disease progression and chromosomal instability. Leukemia 2005 19 : 1192 1197.
3. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007 7 : 441 453.
4. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005 105 : 2640 2653.
5. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000 295 : 139 145.
6. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001 97 : 2440 2448.
7. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center. Cancer 2005 103 : 1659 1669.
8. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 354 : 2542 2551. (Pubitemid 43882350)
9. Le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008 111 : 1834 1839.
10. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009 27 : 4204 4210.
11. Cortes JE, Jones D, O'Brien S, et al. Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. J Clin Oncol 2010 28 : 392 397.
12. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel Abl kinase inhibitor. Science 2004 305 : 399 401.
13. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008 22 : 1200 1206.
14. Hochhaus A, Müller MC, Radich J, et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 2009 23 : 1628 1633.
15. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, Dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005 65 : 9185 9189.
16. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005 102 : 3395 3400.
17. Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007 109 : 2303 2309. (Pubitemid 46425867)
18. Frame MC. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004 117 : 989 998.
19. Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010 28 : 398 404.
20. Golas JM, Lucas J, Etienne C, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005 65 : 5358 5364.
21. Messersmith WA, Rajeshkumar NV, Tan AC, et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther 2009 8 : 1484 1493.
22. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009 101 : 1717 1723.
23. Merseburger AS, Simon A, Waalkes S, Kuczyk MA. Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 2009 9 : 1429 1434.
24. Facchini G, Perri F, Caraglia M, et al. New treatment approaches in renal cell carcinoma. Anticancer Drug 2009 20 : 893 900.
25. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009 69 : 223 240.
26. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009 10 : 470 481.
27. Huang X, Patel S, Ahmed N, Seiter K, Liu D. Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther 2009 2 : 215 219.
28. Masiello D, Gorospe G III., Yang AS. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2009 2 : 46.
29. Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009 114 : 261 263.
30. Lipworth AD, Robert C, Zhu AX. Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): focus on Sorafenib and Sunitinib. Oncology 2009 77 : 257 271.
31. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009 4 : 1 7.
32. Terre C, Eclache V, Rousselot P, et al. France Intergroupe pour la Leucemie Myeloide Chronique. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004 18 : 1340 1346.
33. Fabarius A, Haferlach C, Müller MC, et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007 92 : 834 837.
34. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukaemia. Blood 2006 108 : 2811 2813.
35. Fabarius A, Giehl M, Frank O, et al. Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 2005 19 : 1573 1578.
36. Fabarius A, Giehl M, Frank O, et al. Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with spindle defects and genetic instability. Br J Haematol 2007 138 : 369 373.
37. Fabarius A, Giehl M, Rebacz B, et al. Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 2008 93 : 1145 1154.
38. Giehl M, Fabarius A, Frank O, et al. Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells. Leukemia 2007 21 : 1971 1976.
39. ISCN 2005. An International System for Human Cytogenetic Nomenclature. Shaffer LG, Tommerup N eds)
40. Yuan ZM, Shioya H, Ishiko T, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999 399 : 814 817.
41. Shafman T, Khanna KK, Kedar P, et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997 387 : 520 523.
42. Bertrand P, Lambert S, Joubert C, Lopez BS. Overexpression of mammalian Rad51 does not stimulate tumorigenesis while a dominant-negative Rad51 affects centrosome fragmentation, ploidy and stimulates tumorigenesis, in p53-defective CHO cells. Oncogene 2003 22 : 7587 7592.
43. Daboussi F, Thacker J, Lopez BS. Genetic interactions between RAD51 and its paralogues for centrosome fragmentation and ploidy control, independently of the sensitivity to genotoxic stresses. Oncogene 2005 24 : 3691 3696.
44. Dodson H, Bourke E, Jeffers LJ, et al. Centrosome amplification induced by DNA damage occurs during a prolonged G2 phase and involves ATM. EMBO J 2004 23 : 3864 3873.
45. Tsao AS, He D, Saigal B, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007 6 : 1962 1972.
46. Mamidipudi V, Zhang J, Lee KC, Cartwright CA. RACK1 regulates G1/S progression by suppressing Src kinase activity. Mol Cell Biol 2004 24 : 6788 6798.
47. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005 11 : 6924 6932.
48. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999 31 : 1037 1051.
49. Baumann U, Crosby HA, Ramani P, Kelly DA, Strain AJ. Expression of the stem cell factor receptor c-kit in normal and diseased pediatric liver: identification of a human hepatic progenitor cell? Hepatology 1999 30 : 112 117.
50. Rollman O, Jensen UB, Ostman A, Bolund L, Gústafsdóttir SM, Jensen TG. Platelet derived growth factor (PDGF) responsive epidermis formed from human keratinocytes transduced with the PDGF beta receptor gene. J Invest Dermatol 2003 120 : 742 749.
51. Faraone D, Aguzzi MS, Toietta G, et al. Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia 2009 11 : 732 742.
52. Beeram M, Patnaik A, Rowinsky EK. Regulation of c-Raf-1: therapeutic implications. Clin Adv Hematol Oncol 2003 1 : 476 481.
53. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002 298 : 1912 1934.